Skip to main content
Caplight Logo









Pacylex Pharmaceuticals

Pacylex Pharmaceuticals

Private
EdmontonHealthcare & Life Scienceshttps://pacylex.com/

Last Round

Grant

Jul 1, 2024

Total Funding Raised

$14.96M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Pacylex Pharmaceuticals is a pharmaceutical company that develops N-myristoyltransferase inhibitors as targeted therapies for hematologic and solid cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

biotechnologysmall molecule inhibitorN-myristoyltransferase inhibitorNMT inhibitortargeted cancer therapyoncologydrug discoveryclinical-stage biotechhematologic malignancieszelenirstatADC payloadclinical trialsdrug developmentbiotech startupcancer research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pacylex Pharmaceuticals Comparables

Compare Pacylex Pharmaceuticals with similar companies based on industry and business-model similarity.

Pacylex Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SignalChem Lifesciences Corporation
77%
Novartis
73%
BioTheryX
72%

Pacylex Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 1, 2024
GrantOct 12, 2022
Series AJun 2, 2021
GrantJun 1, 2020
Convertible DebtMar 4, 2020

Key People

Founding team and executive leadership

Luc G. Berthiaume

Chief Scientific Officer and Co-founder

Founding Team

Pacylex Pharmaceuticals Investors

Notable investors and investment history

Pacylex Pharmaceuticals investors
InvestorRounds
United States Department of DefenseGrant
Alberta InnovatesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 598% MoM.

  • May 1, 2025

    Monthly visitors increased 229% MoM.

Pacylex Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pacylex Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pacylex Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdmonton
Employee Range9
Year Founded2012
Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?